Roche Holding AG (SWX:ROP)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 290.52B +24.9% |
| Revenue (ttm) | 62.96B -0.8% |
| Net Income | 12.34B +30.9% |
| EPS | 15.33 +30.6% |
| Shares Out | 796.77M |
| PE Ratio | 23.48 |
| Forward PE | 17.03 |
| Dividend | 9.80 (2.70%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 307,632 |
| Open | 364.30 |
| Previous Close | 360.00 |
| Day's Range | 361.80 - 367.60 |
| 52-Week Range | 258.20 - 375.80 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 377.24 (+3.84%) |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for ROP stock is "Buy." The 12-month stock price target is CHF 377.24, which is an increase of 3.84% from the latest price.
News
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche’s Genentech announces new one-year data from Phase III Meerkat, Sandcat
Genentech, a member of the Roche (RHHBY) Group, announced new one-year data from the Phase III Meerkat and Sandcat studies evaluating investigational vamikibart compared with a sham procedure that mim...
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT s...
Genentech announces FDA approval of Tecentriq combination
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III...
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...
FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab an...
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Zealand Pharma said on Wednesday its experimental drug helped people who are overweight or obese and have type 2 diabetes lose up to 9.2% of their body weight in a mid-stage trial. The Danish compan...
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC. Roche will preconfigure the instruments and...
Alector price target raised to $3 from $2 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $3 from $2 and keeps an Underweight rating on the shares after the company announced that Genentech (RHHBY) has…
Why is Alector Stock (ALEC) 60% Higher Today?
Shares in U.S. biotech firm Alector ($ALEC) surged 60% in pre-market trading today after Swiss drugmaker Roche ($RHHBY) agreed to pay up to $1.27 billion. to license its experimental treatment…
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket tra...
Alector enters exclusive AL050 global licensing agreement with Genentech
Alector (ALEC) announced it has entered into an exclusive global licensing agreement with Genentech, a member of Roche (RHHBY), granting Genentech worldwide rights to develop and commercialize Alector...
Roche’s Genentech reports new data from Voyager study of Vabysmo
Genentech, a member of the Roche (RHHBY) Group, announced new data from the Voyager study evaluating the effectiveness, durability and safety of Vabysmo in wet age-related macular degeneration, diabet...
Roche’s Genentech reports detailed results from evERA Breast Cancer study
Genentech, a member of the Roche (RHHBY) Group, announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly im...
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal Conditions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectivene...
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--evERA results published in The New England Journal of Medicine underscore the potential of investigational giredestrant in ER+ advanced breast ...
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche's leading weight loss and diabetes candidate has posted excellent Phase 2 clinical trial results. The medicine could carve out a solid niche in this field.
Roche unit launches LightMix Newborn TREC/SMN1/HBB kit
Roche (RHHBY) announced that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepti...
Roche’s Genentech announces FDA approves NDA for fenebrutinib
Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s NDA under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kin...
Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Basel, 30 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under prio...
Roche launches newborn screening test for three severe genetic conditions
This test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) simultaneously . Ca...
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hills...
Roche outlines plans to move towards autonomous AI labs
Swiss pharmaceutical giant Roche outlined plans to move towards autonomous AI labs to speed up research and development discovery at its pharma investor day on Monday.
Roche Holding AG Transcript: Pharma Day 2026
Revised summary: Significant progress was made in pipeline quality, financial performance, and modernization, with 20 NMEs targeted for launch by 2030. Strong AI-driven R&D and manufacturing support key launches in oncology, neurology, immunology, ophthalmology, and CVRM, with multiple milestones expected in 2027.
Roche Holding AG Slides: FY 2026
Roche Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 28, 2026.